Sunil Kalia

Sunil Kalia

Auto-generated profile, based on publicly available information

Sunil Kalia

Department of Dermatology and Skin Science University of British Columbia Vancouver British Columbia Canada

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JZJiaying Zhou
Jiaying Zhou
YCYabin Cheng
Yabin Cheng
LTLiren Tang
Liren Tang
MMMagdalena Martinka
Magdalena Martinka
SKSunil Kalia
Sunil Kalia
Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells

20 July 2022 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
JSJonathan Silverberg
Jonathan Silverberg
DADavid N. Adam
David N. Adam
MZMatthew Zirwas
Matthew Zirwas
SKSunil Kalia
Sunil Kalia
JGJan Gutermuth
Jan Gutermuth
SWStephan Weidinger
Stephan Weidinger
Background The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tralokinumab- versus placebo-treated patients achieved the primary endpoints of Investigator’s Global Assessment (IGA) score of 0/1 and 75% improvement in Eczema Area and Severity Index (EASI-75) and all confirmatory endpoints at Week 16. Objective This post hoc analysis investigated the impact of tralokinumab plus TCS on atopic dermatitis (AD) severity, symptoms, and health-related quality of life (QoL) over the entire 32-week treatment period of ECZTRA 3, including all patients initiated on tralokinumab irrespective of the response achieved at Week 16. Methods Patients were randomized 2:1 to receive subcutaneous tralokinumab 300 mg or placebo every 2 weeks (q2w) with TCS as needed for an initial 16 weeks. At Week 16, patients who achieved the clinical response criteria (IGA 0/1 and/or EASI-75) with tralokinumab were re-randomized 1:1 to tralokinumab q2w or every 4 weeks (q4w), with TCS as needed, for another 16 weeks. Patients not achieving the clinical response criteria with tralokinumab received tralokinumab q2w plus TCS from Week 16. All patients randomized to tralokinumab in the initial treatment period were pooled for this analysis, irrespective of response at Week 16 or dosing regimen beyond Week 16. Results Continued tralokinumab (q2w, N = 164; q4w, N = 69) plus TCS treatment provided progressive improvements from Week 16 onwards in AD signs, with 70.2% (177/252) of patients achieving EASI-75 and 50.4% (127/252) achieving EASI-90 at Week 32. Improvements in patient-reported outcomes were observed within the first few weeks of tralokinumab q2w plus TCS treatment and were sustained throughout the 32-week period. At Week 32, patients initiated on tralokinumab q2w plus TCS achieved a relative improvement versus baseline of 70.8% (standard error (SE), 2.4) in eczema-related sleep interference numeric rating scale (NRS) and 66.8% (SE, 3.1) in Dermatology Life Quality Index (DLQI). Mean TCS use during Weeks 16–32 ranged from 9.2 to 13.6 g (SE, 1.2–2.0) q2w. Most patients (89.9% (222/247)) initiated on tralokinumab q2w plus TCS achieved a meaningful improvement in at least one of the three disease domains, including AD signs (EASI-50), symptoms (pruritus NRS improvement ≥ 3), and QoL (DLQI improvement ≥ 4) at Week 16. Of patients initiated on tralokinumab q2w plus TCS, 53.4% (132/247) achieved a clinically meaningful improvement in all three domains at Week 16 (vs. placebo, 28.5% (35/123); p < 0.001). Conclusions Continued tralokinumab treatment plus TCS as needed provides progressive and sustained improvements in AD signs, symptoms, and health-related QoL over 32 weeks. Clinical trial registration NCT03363854; study start date: 22 February 2018; primary completion date: 8 March 2019; study completion date: 26 September 2019. Infographic Video What is the impact of tralokinumab plus topical corticosteroids in adults with moderate-to-severe atopic dermatitis over 32 weeks? (MP4 216,988 KB)

5 November 2017 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
SKSunil Kalia
Sunil Kalia
JZJianhua Zhao
Jianhua Zhao
Haishan ZengHaishan Zeng
Haishan Zeng
DMDavid McLean
David McLean
NKNikiforos Kollias
Nikiforos Kollias
HLHarvey Lui
Harvey Lui

12 October 2015 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
MAMariam Abbas
Mariam Abbas
SKSunil Kalia
Sunil Kalia
Background: Despite its increased incidence and status as the most prevalent cancer in Canada, there is a paucity of epidemiological data on non-melanoma skin cancer (NMSC). Objective: To assess trends of keratinocyte carcinomas (KC) in Canada over 5 decades. Methods: Articles published from 1960 to 2015 on NMSC in Canada were identified through MEDLINE. Six articles met our search criteria. Results: Overall, KC has increased. However, the rate of increase in the past decade has slowed down and decreased in younger age cohorts. Men had higher incidences of KC. In both sexes, the basal cell carcinoma and squamous cell carcinoma ratio was ≥2.5:1. Keratinocyte carcinomas were most commonly located on the head and neck, and increasing rates are occurring on the trunk. Limitations: The methods of registering skin cancer cases vary among different provinces. Conclusion: Keratinocyte carcinomas incidence is overall increasing; however, there may be evidence that the incidence is leveling off and decreasing in younger age cohorts.

13 November 2019 in Translational Biophotonics
Verified
Journal Article
Open access
PDF file
JZJianhua Zhao
Jianhua Zhao
Haishan ZengHaishan Zeng
Haishan Zeng
SKSunil Kalia
Sunil Kalia
HLHarvey Lui
Harvey Lui
The study objective is to evaluate whether incorporating patient demographics into Raman spectral analysis can improve diagnostic performance. In vivo Raman spectra of 731 cases were analyzed by dividing the data into two groups: skin cancers/precancers (malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and actinic keratosis, n = 340) and benign lesions (pigmented nevi and seborrheic keratosis, n = 391). Patient age, gender, skin type and location of the lesion were taken into account in the analysis. Multivariate statistical analysis including principal component and general discriminant analysis and partial least squares (PLS) were utilized for lesion discrimination. Based on PLS analysis, the area under receiver operating characteristic curve was improved from 0.913 to 0.934 (P < .05) after incorporating patient demographics into the algorithm; the specificity was increased from 33.5% to 44.5%, 56.0% to 68.5% and 76.0% to 82.1% for sensitivity of 99%, 95% and 90%, respectively (P < .05 for all sensitivity levels).

1 January 2013 in Dermatologic Clinics
Verified
Journal Article
Closed access
SKSunil Kalia
Sunil Kalia
HLHarvey Lui
Harvey Lui